The company, which has created proprietary language and software platform Antha specifically for biologists, says it will use the cash to gain further traction and expand in the market.

Antha, the company says, is designed to make reproducible and scalable workflows that can be readily edited and shared, and easily automated on labs’ existing equipment.

Synthace CEO Tim Fell said: "Our need to heal, feed, fuel and manufacture for a growing population can be met by unlocking the near infinite power of biology but only by bringing software abstraction and more automation to biological R&D and manufacturing, and by enabling biologists to build atop their collective work. That is what the Antha platform does, and why we are so passionate about realizing its potential."